The FDA is reviewing RSV vaccines, which have drastically lowered infant hospitalizations, a spokesperson confirmed US regulatory officials are re-examining the safety of RSV shots despite no ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations to face scrutiny under Health Secretary Robert F. Kennedy Jr. No safety ...

U.S. health officials are reportedly questioning the safety of several approved therapies to treat respiratory syncytial virus (RSV) in babies. The treatments—specifically, Sanofi and AstraZeneca’s ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory syncytial virus (RSV) vaccine reduced RSV infections and RSV-related ...

The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...

This is read by an automated voice. Please report any issues or inconsistencies here. The leading cause of infant hospitalization, RSV can trigger severe pneumonia and lung infections. Health ...

Read full article: PHOTOS: 1,000-year rain event washes out Eustis roads Donnelly Street in Mount Dora, East Crooked Lake Drive in Eustis closed LAKE COUNTY, Fla. – Gov. Ron DeSantis said Tuesday on ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...

If your patient is pregnant or older than 60 years and due for a respiratory syncytial virus (RSV) shot, now’s the time to act. A major new review highlighted the vaccine’s impact and safety, ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. When Laura Ehrlich gave birth to her ...

Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in ...

For older adults, the vaccine against respiratory syncytial virus (RSV) appears to be most effective in the first year after administration, according to new research that shows the benefits of the ...